In Brief:
Mobius Therapeutics(TM), LLC, developers of Mitosol(TM), announced that it has been awarded a grant of $244,479 under the U.S. Government's Qualifying Therapeutic Discovery Project (QTDP) program. Companies such as Mobius Therapeutics(TM), which cannot currently use a tax credit, were allowed to apply for a cash grant in lieu of a tax credit. Together with a closed handling system, Mitosol(TM) permits safe and efficient delivery of a precise, single dose of ophthalmic mitomycin. "I am pleased that Mobius Therapeutics(TM) has been recognized by this program for having the potential to significantly improve glaucoma surgery for both patients and surgeons," said Ed Timm, President of Mobius Therapeutics(TM), LLC. Mobius Therapeutics(TM), LLC is an early stage venture focused on ophthalmic surgery solutions.
